What is DelSiTech?
DelSiTech operates as a specialized technology platform company dedicated to the development of biodegradable drug delivery systems. Its core innovation, the Silica Matrix, is engineered to transform the treatment paradigm for metabolic diseases and chronic pain by enabling sustained release of therapeutic agents. By focusing on long-acting formulations, the company addresses critical challenges in patient adherence and dosing frequency. Positioned at the intersection of material science and pharmacology, DelSiTech maintains a collaborative business model, partnering with global biopharmaceutical entities to integrate its delivery solutions into diverse therapeutic portfolios. This strategic positioning allows the company to scale its impact while maintaining a lean, innovation-focused operational structure.
How much funding has DelSiTech raised?
DelSiTech has raised a total of $10.8M across 1 funding round:
Other Financing Round
$10.8M
Other Financing Round (2024): $10.8M with participation from DRW Venture Capital and Tolmar
Key Investors in DelSiTech
DRW Venture Capital
DRW Venture Capital is a firm that focuses on investing in early-stage technology companies, providing both capital and strategic guidance to help startups scale their operations.
Tolmar
Tolmar Pharmaceuticals is a fully integrated pharmaceutical company focused on the innovative development, manufacturing, and commercialization of specialty pharmaceuticals across multiple therapeutic areas.
What's next for DelSiTech?
With the recent influx of capital, DelSiTech is well-positioned to accelerate the clinical validation and commercial deployment of its Silica Matrix platform. The company is expected to prioritize the expansion of its partnership network, seeking to integrate its proprietary technology into a broader array of pharmaceutical assets. As the firm transitions into a more mature phase of enterprise-level operations, the focus will likely shift toward optimizing manufacturing scalability and navigating regulatory pathways for its lead candidates. By maintaining its commitment to improving patient outcomes through reduced dosing frequency, DelSiTech is poised to solidify its status as a key enabler in the next generation of specialty pharmaceutical treatments, potentially setting new standards for long-acting drug delivery in the global market.
See full DelSiTech company page
